Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Shubha Srinivas

Pulmonary Disease Annandale, VA Medical Doctor

NPI 1548555998 CMS profile 2791588

3289 Woodburn Rd Ste 350, Annandale, VA 22003

Open in the dashboard

General payments

$5,115

242 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Shubha Srinivas of Annandale, VA is reported in the CMS Open Payments database as having received $5,115 across 242 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 67th percentile of Pulmonary Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $392 11
2024 General $685 16
2023 General $1,097 56
2022 General $1,958 100
2021 General $121 6
2020 General $108 6
2019 General $755 47

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Shubha Srinivas
  • Pulmonary Disease median
  • Middle half of Pulmonary Disease
  • National median

In program year 2025, general payments to Shubha Srinivas were reported at $392. Among 8,914 Pulmonary Disease profiles paid that year, the median was $500 and the middle half received between $124 and $1,893.

Show as a table
Year Shubha Srinivas Pulmonary Disease median Middle half National median
2019 $755 $377 $109–$1,340 $163
2020 $108 $230 $56–$907 $114
2021 $121 $269 $68–$1,072 $132
2022 $1,958 $390 $100–$1,457 $149
2023 $1,097 $419 $114–$1,659 $160
2024 $685 $476 $123–$1,818 $164
2025 $392 $500 $124–$1,893 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $1,089 59 payments
  2. GlaxoSmithKline, LLC. $740 50 payments
  3. Genzyme Corporation $663 28 payments
  4. Electromed, Inc. $322 15 payments
  5. Inari Medical, Inc. $313 2 payments
  6. Regeneron Healthcare Solutions, Inc. $267 11 payments
  7. Amgen Inc. $239 11 payments
  8. Genentech USA, Inc. $221 9 payments
  9. Boehringer Ingelheim Pharmaceuticals, Inc. $218 11 payments
  10. Pulmonx Corporation $200 3 payments
  11. Other $842 43 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $5,038 239 payments
  2. Education $77 3 payments
Products named General payments · program years 2019–2025
  1. DUPIXENT Immunology $656 28 payments
  2. TRELEGY ELLIPTA $410 28 payments
  3. FASENRA $383 19 payments
  4. BREZTRI $357 15 payments
  5. CT THROMBECTOMY SYSTEM KIT $313 2 payments
  6. FLOWTRIEVER CATHETER, S $313 2 payments
  7. SYMBICORT $282 11 payments
  8. DUPIXENT Inflammation And Immunology $267 11 payments
  9. SMARTVEST $264 12 payments
  10. TEZSPIRE $261 11 payments
  11. Other $3,094 130 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 32 drugs

Part D claims

1,376

Median for Pulmonary Disease: 936

Drug cost

$1,406,381

Median for Pulmonary Disease: $487,987

Branded share of claims

61.4%

Median for Pulmonary Disease: 69.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ofev Nintedanib Esylate Brand 39 $719,060
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 266 $317,105
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 84 $90,906
Nucala Mepolizumab Brand 15 $68,280
Dupixent Pen Dupilumab Brand 12 $47,319
Spiriva Respimat Tiotropium Bromide Brand 46 $32,679
Eliquis Apixaban Brand 43 $30,807
Breo Ellipta Fluticasone/Vilanterol Brand 44 $27,077
Advair Hfa Fluticasone Propion/Salmeterol Brand 23 $14,279
Anoro Ellipta Umeclidinium Brm/Vilanterol Tr Brand 12 $11,383

The 10 drugs with the highest cost, of 32 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 9,233 Part D prescribers listed as Pulmonary Disease; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 42 billing codes

Paid by Medicare

$161,884

Of which drugs: $36,585

Medicare patients

476

Average age 77

Services billed

2,625

306 women, 170 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 53%
COPD 52%
Ischemic heart disease 47%
Heart failure 38%
Diabetes 31%
Atrial fibrillation 29%
Chronic kidney disease 29%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg J7613 Office 20 60 $2

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 6 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
  • GENZYME CORPORATION $57
$57 12 —
NUCALA
  • GlaxoSmithKline, LLC. $51
$51 15 —
FASENRA
  • AstraZeneca Pharmaceuticals LP $51
$51 — —
TEZSPIRE
  • AstraZeneca Pharmaceuticals LP $34
$34 — —
XOLAIR
  • Novartis Pharmaceuticals Corporation $16
$16 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 6 in the dashboard with a free account

Records

242 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pulmonary Disease in Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record